store at low temperature
store at -20°C
Elotuzumab(HuLuc 63) is a monoclonal antibody that targets the SLAMF7 receptor.Elotuzumab is a compound that directly activates NK cells and induces antibody-dependent cytotoxicity, and can be used in combination with lenalidomide and dexamethasone (Ld) to treat multiple myeloma.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
1 mg | 在庫あり | ¥ 52,500 |
2 mg | 在庫あり | ¥ 87,000 |
5 mg | 在庫あり | ¥ 158,500 |
10 mg | 在庫あり | ¥ 223,500 |
25 mg | 在庫あり | ¥ 328,500 |
50 mg | 在庫あり | ¥ 443,000 |
100 mg | 在庫あり | ¥ 603,500 |
説明 | Elotuzumab(HuLuc 63) is a monoclonal antibody that targets the SLAMF7 receptor.Elotuzumab is a compound that directly activates NK cells and induces antibody-dependent cytotoxicity, and can be used in combination with lenalidomide and dexamethasone (Ld) to treat multiple myeloma. |
In vivo | Elotuzumab (anti-SLAMF7) was given at 10 mg/kg weekly for the first two treatment cycles (28 days/cycle), followed by 10 mg/kg every other week for all subsequent cycles. Four different Elotuzumab (anti-SLAMF7) combination therapies were administered: 1) Elotuzumab (anti-SLAMF7) and dexamethasone 2) Elotuzumab (anti-SLAMF7), lenalidomide and dexamethasone 3) Elotuzumab (anti-SLAMF7), pomalidomide and dexamethasone and 4) Elotuzumab (anti-SLAMF7), carfilzomib, pomalidomide, and dexamethasone. We found that regardless of Elotuzumab (anti-SLAMF7) combination therapy, all patients treated showed decreased phosphorus levels after initiating Elotuzumab (anti-SLAMF7) treatment with reductions ranging from 12.5% to 44.1% below baseline. Six participants (67%) demonstrated average serum phosphorus at or below 2.5 mg/dL after starting Elotuzumab (anti-SLAMF7) therapy.[2] |
別名 | Elotuzumab (anti-SLAMF7), BMS 901608, PDL 063, HuLuc 63 |
分子量 | N/A |
CAS No. | 915296-00-3 |
store at low temperature
store at -20°C
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Elotuzumab 915296-00-3 Others PDL-063 PDL063 Elotuzumab (anti-SLAMF7) BMS-901608 BMS 901608 PDL 063 anti-SLAMF7 BMS901608 HuLuc 63 Inhibitor inhibitor inhibit